These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36944116)

  • 1. Peripheral Circulating Exosomal-miRNAs Potentially Mediate the Sensitivity to Interferon Treatment in Chronic Hepatitis B Virus Patients.
    Huang Q; Xiao X; Zhuang X; Chen W; Huang Y; Liao J; Wang W; Wang Y; Lu L; Liu Z; Huang J
    Viral Immunol; 2023 Apr; 36(3):209-221. PubMed ID: 36944116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon.
    Hu Q; Wang Q; Zhang Y; Tao S; Zhang X; Liu X; Li X; Jiang X; Huang C; Xu W; Qi X; Chen L; Li Q; Huang Y
    J Med Virol; 2021 Aug; 93(8):4939-4948. PubMed ID: 33666247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a.
    Yang Y; Liu M; Deng Y; Guo Y; Zhang X; Xiang D; Jiang L; You Z; Wu Y; Li M; Mao Q
    Virol J; 2018 Apr; 15(1):73. PubMed ID: 29685146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    Ninomiya M; Kondo Y; Kimura O; Funayama R; Nagashima T; Kogure T; Morosawa T; Tanaka Y; Nakayama K; Shimosegawa T
    J Viral Hepat; 2016 May; 23(5):330-9. PubMed ID: 26924666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    Wu W; Wu D; Yan W; Wang Y; You J; Wan X; Xi D; Luo X; Han M; Ning Q
    J Infect Dis; 2021 Feb; 223(4):686-698. PubMed ID: 32663850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.
    Brunetto MR; Cavallone D; Oliveri F; Moriconi F; Colombatto P; Coco B; Ciccorossi P; Rastelli C; Romagnoli V; Cherubini B; Teilum MW; Blondal T; Bonino F
    PLoS One; 2014; 9(10):e110782. PubMed ID: 25350115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
    Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
    Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients.
    van der Ree MH; Jansen L; Kruize Z; van Nuenen AC; van Dort KA; Takkenberg RB; Reesink HW; Kootstra NA
    J Infect Dis; 2017 May; 215(9):1421-1429. PubMed ID: 28368488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-548c-3p targets TRIM22 to attenuate the Peg-IFN-α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B.
    Lin N; Wang L; Guo Z; Guo S; Liu C; Lin J; Wu S; Xu S; Guo H; Fang F; Fu Y; Ou Q
    Antiviral Res; 2023 May; 213():105584. PubMed ID: 37019306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
    Nagura Y; Matsuura K; Iio E; Fujita K; Inoue T; Matsumoto A; Tanaka E; Nishiguchi S; Kang JH; Matsui T; Enomoto M; Ikeda H; Watanabe T; Okuse C; Tsuge M; Atsukawa M; Tateyama M; Kataoka H; Tanaka Y
    PLoS One; 2022; 17(2):e0263844. PubMed ID: 35157730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection.
    Loukachov VV; van Dort KA; Maurer I; Takkenberg RB; de Niet A; Reesink HW; Willemse SB; Kootstra NA
    Front Cell Infect Microbiol; 2022; 12():790964. PubMed ID: 35719345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.
    Pratedrat P; Chuaypen N; Nimsamer P; Payungporn S; Pinjaroen N; Sirichindakul B; Tangkijvanich P
    PLoS One; 2020; 15(4):e0232211. PubMed ID: 32330203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.
    Fujita K; Mimura S; Iwama H; Nakahara M; Oura K; Tadokoro T; Nomura T; Tani J; Yoneyama H; Morishita A; Oryu M; Himoto T; Nishitsuji H; Shimotohno K; Omata M; Masaki T
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30004437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
    Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
    BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating miR-23b-3p, miR-145-5p and miR-200b-3p are potential biomarkers to monitor acute pain associated with laminitis in horses.
    Lecchi C; Dalla Costa E; Lebelt D; Ferrante V; Canali E; Ceciliani F; Stucke D; Minero M
    Animal; 2018 Feb; 12(2):366-375. PubMed ID: 28689512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of miRNAs associated with dendritic cell dysfunction during acute and chronic hepatitis B virus infection.
    Singh AK; Rooge SB; Varshney A; Vasudevan M; Kumar M; Geffers R; Kumar V; Sarin SK
    J Med Virol; 2021 Jun; 93(6):3697-3706. PubMed ID: 33107616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.